Application of Molecular and Genomic Biomarker Testing in Hematopathology (no CME)-Recorded Webinar

Video Transcription

Video Summary

The Florida Society of Pathologists Precision Medicine Academy recently hosted a webinar on &quot;Application of Molecular and Genomic Biomarker Testing in Hepatopathology,&quot; led by Dr. Marilyn Bui. The session emphasized the integration of molecular genetic testing into hematopathology and its influence on diagnosis, prognosis, and treatment decisions in hematologic malignancies. Esteemed faculty, including Dr. Rhys Cardero and Dr. Knepper, discussed the evolution and significance of various molecular techniques, like next-generation sequencing (NGS), karyotyping, and FISH in identifying genomic alterations critical in hematology.NGS was highlighted as transformative for clinical decision-making, offering precise prognostic information and guiding therapy selection based on specific mutations. The webinar showcased use cases in diseases such as MDS, AML, CLL, and various lymphomas, outlining how genomic profiling aids in subclassification and risk stratification, influencing treatment strategies. It highlighted the significance of identifying germline mutations and the necessity of rigorous pre-analytical to post-analytical quality assurance in processing samples for genomic testing.Case studies illustrated the clinical application of NGS results in real-world scenarios, underscoring the necessity of comprehensive reports that integrate clinical, morphological, and molecular data for optimal patient management. The session concluded with a brief Q&amp;A, discussing biomarkers like IDH1 across different tumor types, stressing the importance of disease-specific evaluations for genomic alterations. Attendees were encouraged to access recorded sessions for continuing education through FSP's Learning Center.

Keywords

Florida Society of Pathologists

Precision Medicine Academy

molecular genomic biomarker testing

hepatopathology webinar

hematopathology

next-generation sequencing (NGS)

karyotyping

FISH (fluorescence in situ hybridization)

hematologic malignancies (MDS AML CLL lymphomas)

genomic profiling and risk stratification